Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
| Title: | Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol |
|---|---|
| Authors: | Attard, G; Murphy, L; Clarke, NW; Cross, W; Jones, RJ; Parker, CC; Gillessen, S; Cook, A; Brawley, C; Amos, CL; Atako, N; Pugh, C; Buckner, M; Chowdhury, S; Malik, Z; Russell, JM; Gilson, C; Rush, H; Bowen, J; Lydon, A; Pedley, I; O'Sullivan, JM; Birtle, A; Gale, J; Srihari, N; Thomas, C; Tanguay, J; Wagstaff, J; Das, P; Gray, E; Alzoueb, M; Parikh, O; Robinson, A; Syndikus, I; Wylie, J; Zarkar, A; Thalmann, G; de Bono, JS; Dearnaley, DP; Mason, MD; Gilbert, D; Langley, RE; Millman, R; Matheson, D; Sydes, MR; Brown, LC; Parmar, MKB; James, ND; Jones, E; Hyde, K; Glen, H; Needleman, S; McGovern, U; Sheehan, D; Paisey, S; Shaffer, R; Beresford, M; Porfiri, E; Fackrell, D; Lee, L; Sreenivasan, T; Brock, S; Brown, S; Bahl, A; Smith-Howell, M; Woodward, C; Phan, MD; Mazhar, D; Narahari, K; Douglas, F; Kumar, A; Hamid, A; Ibrahim, A; Muthukumar, D; Simms, M; Worlding, J; Tran, A; Kagzi, M; Pezaro, C; Sivoglo, V; Masters, B; Keng-Koh, P; Manetta, C; McLaren, D; Gupta, N; Boussios, S; Taylor, H; Graham, J; Perna, C; Melcher, L; Grant, W; Sabharwal, A; Hofmann, U; Dealey, R; McPhail, N; Brierly, R; Capaldi, L; Sidek, N; Whelan, P; Robson, P |
| Publisher Information: | Elsevier BV |
| Publication Year: | 2022 |
| Collection: | The University of Liverpool Repository |
| Description: | Background: Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to ADT in this patient population. Methods: These open-label, phase 3 trials were done at 113 sites in the UK and Switzerland. Eligible patients (no age restrictions) had high-risk (defined as node positive or, if node negative, having at least two of the following: tumour stage T3 or T4, Gleason sum score of 8–10, and prostate-specific antigen [PSA] concentration ≥40 ng/mL) or relapsing with high-risk features (≤12 months of total ADT with an interval of ≥12 months without treatment and PSA concentration ≥4 ng/mL with a doubling time of |
| Document Type: | article in journal/newspaper |
| File Description: | application/pdf |
| Language: | English |
| ISSN: | 0140-6736 |
| Relation: | https://livrepository.liverpool.ac.uk/3171555/1/Abiraterone%20acetate%20and%20prednisolone%20with%20or%20without%20enzalutamide%20for%20high-risk%20non-metastatic%20prostate%20cancer%20a%20meta-analys.pdf; Collapse authors list. Attard, G, Murphy, L, Clarke, NW, Cross, W, Jones, RJ orcid:0000-0001-5608-001X , Parker, CC, Gillessen, S, Cook, A, Brawley, C, Amos, CL et al (show 90 more authors) , Atako, N, Pugh, C, Buckner, M, Chowdhury, S, Malik, Z, Russell, JM, Gilson, C, Rush, H, Bowen, J, Lydon, A, Pedley, I, O'Sullivan, JM, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzoueb, M, Parikh, O, Robinson, A, Syndikus, I, Wylie, J, Zarkar, A, Thalmann, G, de Bono, JS, Dearnaley, DP, Mason, MD, Gilbert, D, Langley, RE, Millman, R, Matheson, D, Sydes, MR, Brown, LC, Parmar, MKB, James, ND, Jones, E, Hyde, K, Glen, H, Needleman, S, McGovern, U, Sheehan, D, Paisey, S, Shaffer, R, Beresford, M orcid:0000-0002-5400-9911 , Porfiri, E, Fackrell, D, Lee, L, Sreenivasan, T, Brock, S, Brown, S, Bahl, A, Smith-Howell, M, Woodward, C, Phan, MD, Mazhar, D, Narahari, K, Douglas, F, Kumar, A, Hamid, A, Ibrahim, A, Muthukumar, D, Simms, M, Worlding, J, Tran, A, Kagzi, M, Pezaro, C, Sivoglo, V, Masters, B, Keng-Koh, P, Manetta, C, McLaren, D, Gupta, N, Boussios, S, Taylor, H, Graham, J, Perna, C, Melcher, L, Grant, W, Sabharwal, A, Hofmann, U, Dealey, R, McPhail, N, Brierly, R, Capaldi, L, Sidek, N, Whelan, P and Robson, P (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol Lancet, 399 (10323). pp. 447-460. ISSN 0140-6736, 1474-547X |
| DOI: | 10.1016/s0140-6736(21)02437-5 |
| Availability: | https://livrepository.liverpool.ac.uk/3171555/; https://doi.org/10.1016/s0140-6736(21)02437-5 |
| Accession Number: | edsbas.97AE1A8A |
| Database: | BASE |